SCHEMBL4667552

SCHEMBL4667552

Clc1ccc(C(OCCOC(c2ccc(Cl)cc2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.54
TDO2 P48775 3/20 0.54
SLC6A2 P23975 3/20 0.53
SLC6A4 P31645 3/20 0.53
SLC6A3 Q01959 3/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
CHRM2 P08172 2/20 0.53
KCNH2 Q12809 2/20 0.53
CYP1A2 P05177 1/20 0.53
TSHR P16473 1/20 0.53
HIF1A Q16665 1/20 0.53
SLC22A1 O15245 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
CHRM1 P11229 1/20 0.53
DRD1 P21728 1/20 0.53
TBXA2R P21731 1/20 0.53
ADRA1A P35348 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5190981 0.91 CYP3A4 (0.64) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL4669314 0.91 CYP3A4 (0.64) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL14160199 0.89 LMNA (0.49) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL7583717 0.89 LMNA (0.51) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL423397 0.87 LMNA (0.54) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL7630650 0.87 LMNA (0.50) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL7634181 0.87 SLC6A2 (0.47) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL9242920 0.82 CYP3A4 (0.59) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL7429799 0.81 IDO1 (0.50) IDO1TDO2SLC6A2SLC6A4SLC6A3
SCHEMBL30356264 0.80 CHRM2 (0.57) IDO1TDO2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed